Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gynecology

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 161 articles:
HTML format
Text format



Single Articles


    May 2018
  1. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Utilization of Hysterectomy Following Chemoradiation for IB2/IIA2 Cervical Cancer in the National Cancer Data Base.
    Anticancer Res. 2018;38:3175-3179.
    PubMed     Text format     Abstract available


  2. LUMACHI F, Basso SMM, Camozzi V, Spaziante R, et al
    Bone Mineral Density as a Potential Predictive Factor for Luminal-type Breast Cancer in Postmenopausal Women.
    Anticancer Res. 2018;38:3049-3054.
    PubMed     Text format     Abstract available


  3. KISS I, Kolostova K, Matkowski R, Jedryka M, et al
    Correlation Between Disease Stage and the Presence of Viable Circulating Tumor Cells in Endometrial Cancer.
    Anticancer Res. 2018;38:2983-2987.
    PubMed     Text format     Abstract available


  4. PHELIPPEAU J, Rouzier R, Koskas M
    Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database.
    Anticancer Res. 2018;38:2977-2982.
    PubMed     Text format     Abstract available


  5. SLETTEN ET, Arnes M, Vereide AB, Orbo A, et al
    Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
    Anticancer Res. 2018;38:2883-2889.
    PubMed     Text format     Abstract available


  6. SUNG JY, Jung YY, Kim HS
    Clinicopathological Characteristics and KRAS Mutation Status of Endometrial Mucinous Metaplasia and Carcinoma.
    Anticancer Res. 2018;38:2779-2786.
    PubMed     Text format     Abstract available


  7. LIN CC, Kuo CL, Huang YP, Chen CY, et al
    Demethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells via Inhibition of NF-kappaB Pathways.
    Anticancer Res. 2018;38:2761-2769.
    PubMed     Text format     Abstract available


  8. ARGYRI E, Tsimplaki E, Papatheodorou D, Daskalopoulou D, et al
    Recent Trends in HPV Infection and Type Distribution in Greece.
    Anticancer Res. 2018;38:3079-3084.
    PubMed     Text format     Abstract available


    April 2018
  9. SCHUSTER S, Joura E, Kohlberger P
    Natural History of Squamous Intraepithelial Lesions in Pregnancy and Mode of Delivery.
    Anticancer Res. 2018;38:2439-2442.
    PubMed     Text format     Abstract available


  10. PERRIN M, Bentivegna E, Bonneau C, Uzan C, et al
    Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery.
    Anticancer Res. 2018;38:2247-2252.
    PubMed     Text format     Abstract available


  11. TRYBUS W, Krol T, Trybus E, Stachurska A, et al
    Induction of Mitotic Catastrophe in Human Cervical Cancer Cells After Administration of Aloe-emodin.
    Anticancer Res. 2018;38:2037-2044.
    PubMed     Text format     Abstract available


    March 2018
  12. GADDUCCI A, Guerrieri ME, Cosio S, Fabrini MG, et al
    Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study.
    Anticancer Res. 2018;38:1695-1703.
    PubMed     Text format     Abstract available


  13. FILIPESCU A, Balescu I, Bacalbasa N
    Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer.
    Anticancer Res. 2018;38:1659-1663.
    PubMed     Text format     Abstract available


  14. STOPE MB, Cernat V, Kaul A, Diesing K, et al
    Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma.
    Anticancer Res. 2018;38:1547-1550.
    PubMed     Text format     Abstract available


  15. KOENSGEN D, Weiss M, Assmann K, Brucker SY, et al
    Characterization and Management of Borderline Ovarian Tumors - Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald.
    Anticancer Res. 2018;38:1539-1545.
    PubMed     Text format     Abstract available


  16. CANLORBE G, Touboul C, Chargari C, Bentivegna E, et al
    Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer.
    Anticancer Res. 2018;38:1517-1523.
    PubMed     Text format     Abstract available


  17. FAHLEN M, Zhang H, Lofgren L, Masironi B, et al
    Expression of Progesterone and Androgen Receptors in the Breast of Premenopausal Women, Considering Menstrual Phase.
    Anticancer Res. 2018;38:1499-1510.
    PubMed     Text format     Abstract available


  18. CHUNG EH, Brady PC, Smith KK, Davis MR, et al
    Combined Oocyte Retrieval and Robot-assisted Hysterectomy in a Super Morbidly Obese Patient with Endometrial Carcinoma.
    Anticancer Res. 2018;38:1467-1470.
    PubMed     Text format     Abstract available


  19. FISZER-MALISZEWSKA L, Laczmanski L, Dolinska A, Jagas M, et al
    Polymorphisms of ABCB1, CYP3A4 and CYP3A5 Genes in Ovarian Cancer and Treatment Response in Poles.
    Anticancer Res. 2018;38:1455-1459.
    PubMed     Text format     Abstract available


  20. NA K, Sung JY, Kim HS
    Clinicopathological Characteristics of High-grade Squamous Intraepithelial Lesions Involving Condyloma Acuminatum.
    Anticancer Res. 2018;38:1767-1774.
    PubMed     Text format     Abstract available


    February 2018
  21. HATA M, Koike I, Miyagi E, Asai-Sato M, et al
    Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care.
    Anticancer Res. 2018;38:1033-1040.
    PubMed     Text format     Abstract available


  22. KALAMPOKAS E, Young H, Bednarek A, Habib M, et al
    Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre.
    Anticancer Res. 2018;38:923-928.
    PubMed     Text format     Abstract available


  23. MATUURA H, Miyamoto M, Takano M, Soyama H, et al
    Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
    Anticancer Res. 2018;38:717-722.
    PubMed     Text format     Abstract available


  24. ZHAO Y, Xiong GW, Zhang XW, Hang BO, et al
    Is Ki-67 of Diagnostic Value in Distinguishing Between Partial and Complete Hydatidiform Moles? A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1105-1110.
    PubMed     Text format     Abstract available


    January 2018
  25. BRUCKNER HW, Gurell D, Hirschfeld A
    Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
    Anticancer Res. 2018;38:547-552.
    PubMed     Text format     Abstract available


  26. OKONOGI N, Wakatsuki M, Kato S, Shiba S, et al
    Long-term Outcomes of Carbon-ion Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:457-463.
    PubMed     Text format     Abstract available


  27. BACALBASA N, Balescu I, Brasoveanu V, Anca AF, et al
    Debulking Surgery for Pelvic Recurrence After Surgically-treated Tubal Gestational Choriocarcinoma - A Case Report and Literature Review.
    Anticancer Res. 2018;38:423-426.
    PubMed     Text format     Abstract available


  28. MIYAMOTO M, Takano M, Aoyama T, Soyama H, et al
    Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition.
    Anticancer Res. 2018;38:301-306.
    PubMed     Text format     Abstract available


  29. KOBIERZYCKI C, Piotrowska A, Latkowski K, Zabel M, et al
    Correlation of Pyruvate Kinase M2 Expression with Clinicopathological Data in Ovarian Cancer.
    Anticancer Res. 2018;38:295-300.
    PubMed     Text format     Abstract available


  30. SOUKUP V, Capoun O, Pesl M, Sobotka R, et al
    Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
    Anticancer Res. 2018;38:239-246.
    PubMed     Text format     Abstract available


  31. PELISSIER A, Franke O, Darai E, Houvenaeghel G, et al
    Value of Diaphragmatic Surgery During Interval Debulking Surgery.
    Anticancer Res. 2018;38:411-416.
    PubMed     Text format     Abstract available


    December 2017
  32. LEE HJ, Lee YH, Chong GO, Hong DG, et al
    Robotic-assisted Transperitoneal Infrarenal Para-aortic Lymphadenectomy for Gynecological Malignancies: Comparison with a Laparoscopic Approach.
    Anticancer Res. 2017;37:7087-7093.
    PubMed     Text format     Abstract available


  33. NIIBE Y, Onda T, Matsuo K, Inoue Y, et al
    Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results.
    Anticancer Res. 2017;37:6983-6988.
    PubMed     Text format     Abstract available


  34. MOURAD WF, Packianathan S, Yan W, Pishgou M, et al
    Reliable Radiation Technique to Minimize Ovarian Dose During Radiation Prophylaxis of Heterotopic Ossification.
    Anticancer Res. 2017;37:6929-6935.
    PubMed     Text format     Abstract available


  35. TINELLI G, Cappuccio S, Parente E, Fagotti A, et al
    Resectability and Vascular Management of Retroperitoneal Gynecological Malignancies: A Large Single-institution Case-Series.
    Anticancer Res. 2017;37:6899-6906.
    PubMed     Text format     Abstract available


  36. DUCOULOMBIER S, Golfier F, Colomban O, Benayoun D, et al
    Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.
    Anticancer Res. 2017;37:6879-6886.
    PubMed     Text format     Abstract available


  37. KOENSGEN D, Besic I, Gumbel D, Kaul A, et al
    Cold Atmospheric Plasma (CAP) and CAP-Stimulated Cell Culture Media Suppress Ovarian Cancer Cell Growth - A Putative Treatment Option in Ovarian Cancer Therapy.
    Anticancer Res. 2017;37:6739-6744.
    PubMed     Text format     Abstract available


  38. NA K, Sung JY, Kim HS
    TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern.
    Anticancer Res. 2017;37:6697-6703.
    PubMed     Text format     Abstract available


  39. KUITTINEN T, Rovio P, Staff S, Luukkaala T, et al
    Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro.
    Anticancer Res. 2017;37:6575-6581.
    PubMed     Text format     Abstract available


  40. RAPI V, Dogan A, Schultheis B, Hartmann F, et al
    Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
    Anticancer Res. 2017;37:6911-6920.
    PubMed     Text format     Abstract available


  41. BAVELLONI A, Ramazzotti G, Poli A, Piazzi M, et al
    MiRNA-210: A Current Overview.
    Anticancer Res. 2017;37:6511-6521.
    PubMed     Text format     Abstract available


    November 2017
  42. KIM SM, Rhee YH, Kim JS
    The Anticancer Effects of Radachlorin-mediated Photodynamic Therapy in the Human Endometrial Adenocarcinoma Cell Line HEC-1-A.
    Anticancer Res. 2017;37:6251-6258.
    PubMed     Text format     Abstract available


  43. YANG Y, Li X, Mamouni K, Kucuk O, et al
    Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer.
    Anticancer Res. 2017;37:6235-6243.
    PubMed     Text format     Abstract available


  44. NAKATANI M, Watari H, Mitamura T, Wang L, et al
    The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo.
    Anticancer Res. 2017;37:6125-6132.
    PubMed     Text format     Abstract available


  45. TRYBUS W, Krol T, Trybus E, Kopacz-Bednarska A, et al
    Changes in the Lysosomal System of Cervical Cancer Cells Induced by Emodin Action.
    Anticancer Res. 2017;37:6087-6096.
    PubMed     Text format     Abstract available


  46. GADDUCCI A, Guerrieri ME
    Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    Anticancer Res. 2017;37:5955-5965.
    PubMed     Text format     Abstract available


    October 2017

  47. Translational Advances in Gynecologic Cancers. 1st Edition.
    Anticancer Res. 2017;37:5907.
    PubMed     Text format    


  48. BACALBASA N, Balescu I, Filipescu A
    Debulking Surgery for Clear Cell Carcinoma of the Ovary - A Case Report and Literature Review.
    Anticancer Res. 2017;37:5707-5711.
    PubMed     Text format     Abstract available


  49. SHIBA S, Okonogi N, Kato S, Wakatsuki M, et al
    Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers.
    Anticancer Res. 2017;37:5577-5583.
    PubMed     Text format     Abstract available


  50. PARK CK, Kim HS
    Clinicopathological Characteristics of Ovarian Sclerosing Stromal Tumor with an Emphasis on TFE3 Overexpression.
    Anticancer Res. 2017;37:5441-5447.
    PubMed     Text format     Abstract available


  51. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Text format     Abstract available


  52. KAWAHARA H, Akiba T, Yanaga K
    Transanal Assisted Resection with Closure of Anal Canal for Lower Rectal Diseases.
    Anticancer Res. 2017;37:5767-5769.
    PubMed     Text format     Abstract available


  53. GUNGORDUK K, Asicioglu O, Braicu EI, Almuheimid J, et al
    The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.
    Anticancer Res. 2017;37:5609-5616.
    PubMed     Text format     Abstract available


    September 2017
  54. RICCIARDI E, Tomao F, Aletti G, Bazzurini L, et al
    Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
    Anticancer Res. 2017;37:5241-5248.
    PubMed     Text format     Abstract available


  55. KIM M, Kim H, Suh DH, Kim K, et al
    Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer.
    Anticancer Res. 2017;37:5087-5094.
    PubMed     Text format     Abstract available


  56. THEODORE C, Levaillant JM, Capmas P, Chabi N, et al
    MRI and Ultrasound Fusion Imaging for Cervical Cancer.
    Anticancer Res. 2017;37:5079-5085.
    PubMed     Text format     Abstract available


  57. KIM BW, Cho H, Ylaya K, Kitano H, et al
    Bcl-2-like Protein 11 (BIM) Expression Is Associated with Favorable Prognosis for Patients with Cervical Cancer.
    Anticancer Res. 2017;37:4873-4879.
    PubMed     Text format     Abstract available


  58. ANNEDE P, Darreon J, Benkemouche A, Valdenaire S, et al
    Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy.
    Anticancer Res. 2017;37:5133-5139.
    PubMed     Text format     Abstract available


  59. VORA M, Alattia LA, Ansari J, Ong M, et al
    Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
    Anticancer Res. 2017;37:4821-4825.
    PubMed     Text format     Abstract available


  60. SUKOVAS A, Cesna V, Jasukaitiene A, Barauskas G, et al
    Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter?
    Anticancer Res. 2017;37:5011-5018.
    PubMed     Text format     Abstract available


  61. KASE S, Ishijima K, Uraki T, Suimon Y, et al
    Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa.
    Anticancer Res. 2017;37:5001-5004.
    PubMed     Text format     Abstract available


    August 2017
  62. WANG SG, Mu N, Sun HY
    Effect of Interventional Therapy on the Expression of Survivin mRNA in Cervical Cancer.
    Anticancer Res. 2017;37:4707-4710.
    PubMed     Text format     Abstract available


  63. CUI Y, Wu BO, Flamini V, Evans BAJ, et al
    Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells.
    Anticancer Res. 2017;37:4415-4424.
    PubMed     Text format     Abstract available


  64. BIGLIA N, Zanfagnin V, Daniele A, Robba E, et al
    Lower Body Lymphedema in Patients with Gynecologic Cancer.
    Anticancer Res. 2017;37:4005-4015.
    PubMed     Text format     Abstract available


  65. SUN L, Zhang J, Yang Q, Si Y, et al
    Synergistic Effects of SAM and Selenium Compounds on Proliferation, Migration and Adhesion of HeLa Cells.
    Anticancer Res. 2017;37:4433-4441.
    PubMed     Text format     Abstract available


  66. WANG L, Qi Y, Xiong Y, Peng Z, et al
    Ezrin-Radixin-Moesin Binding Phosphoprotein 50 (EBP50) Suppresses the Metastasis of Breast Cancer and HeLa Cells by Inhibiting Matrix Metalloproteinase-2 Activity.
    Anticancer Res. 2017;37:4353-4360.
    PubMed     Text format     Abstract available


    July 2017
  67. MIYATA K, Yotsumoto F, Fukagawa S, Kiyoshima C, et al
    Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer.
    Anticancer Res. 2017;37:3955-3960.
    PubMed     Text format     Abstract available


  68. MURAKAMI M, Kagami S, Nguyen TT, Koi C, et al
    Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
    Anticancer Res. 2017;37:3911-3915.
    PubMed     Text format     Abstract available


  69. KURITA T, Thi TN, Koi C, Murakami M, et al
    Expression of N-Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer.
    Anticancer Res. 2017;37:3905-3910.
    PubMed     Text format     Abstract available


  70. FUKAGAWA S, Yotsumoto F, Odawara T, Manabe S, et al
    Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy.
    Anticancer Res. 2017;37:3891-3896.
    PubMed     Text format     Abstract available


  71. KUMAR A, Torres ML, Cliby WA, Kalli KR, et al
    Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer.
    Anticancer Res. 2017;37:3673-3677.
    PubMed     Text format     Abstract available


  72. UEDA T, Tsubamoto H, Inoue K, Sakata K, et al
    Itraconazole Modulates Hedgehog, WNT/beta-catenin, as well as Akt Signalling, and Inhibits Proliferation of Cervical Cancer Cells.
    Anticancer Res. 2017;37:3521-3526.
    PubMed     Text format     Abstract available


  73. HASHIMOTO K, Horibe YU, Ezaki J, Kanno T, et al
    Laparoscopically Removed Streak Gonad Revealed Gonadoblastoma in Frasier Syndrome.
    Anticancer Res. 2017;37:3975-3979.
    PubMed     Text format     Abstract available


  74. JANG MI, Sung JY, Kim JY, Kim HS, et al
    Clinicopathological Characteristics of Metaplastic Papillary Tumor of the Fallopian Tube.
    Anticancer Res. 2017;37:3693-3701.
    PubMed     Text format     Abstract available


  75. MARIAMPILLAI AI, Cruz JPD, Suh J, Sivapiragasam A, et al
    Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
    Anticancer Res. 2017;37:3649-3656.
    PubMed     Text format     Abstract available


    June 2017
  76. OPRESCU DN, Bacalbasa N, Balescu I, Filipescu A, et al
    Urinary Tract Resections in Advanced-stage Cervical Cancer - A Series of Eight Cases.
    Anticancer Res. 2017;37:3271-3276.
    PubMed     Text format     Abstract available


  77. NA K, Kim EK, Jang W, Kim HS, et al
    CTNNB1 Mutations in Ovarian Microcystic Stromal Tumors: Identification of a Novel Deletion Mutation and the Use of Pyrosequencing to Identify Reported Point Mutation.
    Anticancer Res. 2017;37:3249-3258.
    PubMed     Text format     Abstract available


  78. MUALLEM MZ, Parashkevova A, Almuheimid J, Richter R, et al
    Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.
    Anticancer Res. 2017;37:3157-3161.
    PubMed     Text format     Abstract available


  79. HONDA KI, Asada R, Kageyama K, Fukuda T, et al
    Protein Complex of Fibrinogen Gamma Chain and Complement Factor H in Ovarian Cancer Patient Plasma.
    Anticancer Res. 2017;37:2861-2866.
    PubMed     Text format     Abstract available


  80. YAMAUCHI K, Afroze SH, Mitsunaga T, McCormick TC, et al
    3,4',7-O-trimethylquercetin Inhibits Invasion and Migration of Ovarian Cancer Cells.
    Anticancer Res. 2017;37:2823-2829.
    PubMed     Text format     Abstract available


  81. DIAB Y, Muallem MZ
    Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature.
    Anticancer Res. 2017;37:2809-2815.
    PubMed     Text format     Abstract available


    May 2017
  82. PRESL J, Ovesna P, Novotny Z, Vlasak P, et al
    Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.
    Anticancer Res. 2017;37:2697-2702.
    PubMed     Text format     Abstract available


  83. BACALBASA N, Balescu I, Marcu M, Oprescu DN, et al
    Solitary Splenic Metastasis After Surgically-treated Cervical Cancer - A Case Report and Literature Review.
    Anticancer Res. 2017;37:2615-2618.
    PubMed     Text format     Abstract available


  84. NA K, Park SY, Kim HS
    Clinicopathological Characteristics of Primary Ovarian Adenomyoma: A Single-institutional Experience.
    Anticancer Res. 2017;37:2565-2574.
    PubMed     Text format     Abstract available


  85. KIM JY, Na K, Kim HS
    Clinicopathological Characteristics of Mitotically-active Cellular Fibroma of the Ovary: A Single-institutional Experience.
    Anticancer Res. 2017;37:2557-2564.
    PubMed     Text format     Abstract available


  86. SLETTEN ET, Arnes M, Lysa LM, Moe BT, et al
    Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Anticancer Res. 2017;37:2529-2536.
    PubMed     Text format     Abstract available


  87. ALAVI S, Eckes L, Kratschell R, Taube ET, et al
    Pleomorphic Rhabdomyosarcoma of the Uterus - Case Report and a Systematic Review of the Literature.
    Anticancer Res. 2017;37:2509-2514.
    PubMed     Text format     Abstract available


  88. MUALLEM MZ, Henrich W, Braun T, Sehouli J, et al
    Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review.
    Anticancer Res. 2017;37:2487-2490.
    PubMed     Text format     Abstract available


  89. MAYER S, Gabriel B, Erbes T, Timme-Bronsert S, et al
    Cyr61 Expression Pattern and Association with Clinicopathological Factors in Patients with Cervical Cancer.
    Anticancer Res. 2017;37:2451-2456.
    PubMed     Text format     Abstract available


  90. NA K, Sung JY, Kim HS
    Stromal p16 Overexpression in Adult Granulosa Cell Tumors of the Ovary.
    Anticancer Res. 2017;37:2437-2444.
    PubMed     Text format     Abstract available


  91. HOLZMANN C, Koczan D, Loening T, Rommel B, et al
    Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22.
    Anticancer Res. 2017;37:2233-2237.
    PubMed     Text format     Abstract available


    April 2017
  92. BRADY PC, Soiffer RJ, Ginsburg ES
    Continuation of a Levonorgestrel Intrauterine Device During Hematopoietic Stem Cell Transplant: A Case Report.
    Anticancer Res. 2017;37:1985-1987.
    PubMed     Text format     Abstract available


  93. LEANDERSSON P, Granasen G, Borgfeldt C
    Ovarian Cancer Surgery - A Population-based Registry Study.
    Anticancer Res. 2017;37:1837-1845.
    PubMed     Text format     Abstract available


  94. PARK GB, Kim D
    PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
    Anticancer Res. 2017;37:1805-1818.
    PubMed     Text format     Abstract available


  95. KLEJEWSKI A, Swierczewska M, Zaorska K, Brazert M, et al
    New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.
    Anticancer Res. 2017;37:1625-1636.
    PubMed     Text format     Abstract available


  96. HAYASHI T, Ichimura T, Kasai M, Sano K, et al
    Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination.
    Anticancer Res. 2017;37:1765-1772.
    PubMed     Text format     Abstract available


    March 2017

  97. Ovarian Cancers. Advances Through International Research Cooperation (GINECO, ENGOT, GCIG).
    Anticancer Res. 2017;37:1543-1544.
    PubMed     Text format    


  98. SEKIDO Y, Ohigashi S, Takahashi T, Hayashi N, et al
    Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
    Anticancer Res. 2017;37:1425-1431.
    PubMed     Text format     Abstract available


  99. GADDUCCI A, Barsotti C, Laliscia C, Cosio S, et al
    Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer: a Preliminary Analysis.
    Anticancer Res. 2017;37:1249-1255.
    PubMed     Text format     Abstract available


  100. DOGAN A, Schultheis B, Rezniczek GA, Hilal Z, et al
    Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature.
    Anticancer Res. 2017;37:969-978.
    PubMed     Text format     Abstract available


  101. VAN SN, Khac MN, Dimberg J, Matussek A, et al
    Prevalence of Cervical Infection and Genotype Distribution of Human Papilloma Virus Among Females in Da Nang, Vietnam.
    Anticancer Res. 2017;37:1243-1247.
    PubMed     Text format     Abstract available


    February 2017
  102. EL-BALAT A, Sanger N, Karn T, Becker S, et al
    IMP3 Expression in Borderline Tumors of the Ovary.
    Anticancer Res. 2017;37:583-588.
    PubMed     Text format     Abstract available


  103. TSUBAMOTO H, Inoue K, Sakata K, Ueda T, et al
    Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells.
    Anticancer Res. 2017;37:515-519.
    PubMed     Text format     Abstract available


    January 2017

  104. Early Nutrition and Lifestyle Factors. Effects on First Trimester Placenta.
    Anticancer Res. 2017;37:372-373.
    PubMed     Text format    


  105. RIZOU N, Moris D, Pikoulis E, Dimitrokallis N, et al
    Minimally Invasive Lymphadenectomy in Uterine Cervical Cancer: A Systematic Review.
    Anticancer Res. 2017;37:335-342.
    PubMed     Text format     Abstract available


  106. CHO O, Noh OK, Oh YT, Chang SJ, et al
    Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer.
    Anticancer Res. 2017;37:327-334.
    PubMed     Text format     Abstract available


  107. MURAKAMI T, Murata T, Kawaguchi K, Kiyuna T, et al
    Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.
    Anticancer Res. 2017;37:61-65.
    PubMed     Text format     Abstract available


    December 2016
  108. NICOLETTO MO, Casarin A, Baldoni A, Rulli E, et al
    Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.
    Anticancer Res. 2016;36:6541-6546.
    PubMed     Text format     Abstract available


  109. CHECK JH, Check D, Wilson C, Lofberg P, et al
    Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
    Anticancer Res. 2016;36:6511-6513.
    PubMed     Text format     Abstract available


  110. SANTALA S, Talvensaari-Mattila A, Soini Y, Kuvaja P, et al
    Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma.
    Anticancer Res. 2016;36:6467-6473.
    PubMed     Text format     Abstract available


  111. ANASTASI E, Capoccia D, Granato T, Silecchia G, et al
    Implementing the Risk of Ovarian Malignancy Algorithm Adding Obesity as a Predictive Factor.
    Anticancer Res. 2016;36:6425-6429.
    PubMed     Text format     Abstract available


  112. LEE YY, Jeon HK, Lee J, Hong JE, et al
    Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells.
    Anticancer Res. 2016;36:6381-6388.
    PubMed     Text format     Abstract available


    November 2016
  113. STARBUCK KD, Drake RD, Budd GT, Rose PG, et al
    Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
    Anticancer Res. 2016;36:6161-6164.
    PubMed     Text format     Abstract available


  114. VINDEVOGEL E, Baert T, VAN Hoylandt A, Verbist G, et al
    The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer.
    Anticancer Res. 2016;36:5781-5792.
    PubMed     Text format     Abstract available


  115. LAPINSKA K, Housman G, Byler S, Heerboth S, et al
    The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells.
    Anticancer Res. 2016;36:5731-5742.
    PubMed     Text format     Abstract available


    October 2016
  116. JANSSEN S, Bajrovic A, Schild SE, Rades D, et al
    A Scoring Instrument to Predict the Survival Prognoses of Patients with Metastatic Epidural Spinal Cord Compression from Gynecological Malignancies.
    Anticancer Res. 2016;36:5469-5472.
    PubMed     Text format     Abstract available


  117. KOSKAS M, Depreeuw J, Moens S, Annibali D, et al
    Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.
    Anticancer Res. 2016;36:5381-5384.
    PubMed     Text format     Abstract available


  118. ROSENDAHL M, Mosgaard BJ, Hogdall C
    The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer.
    Anticancer Res. 2016;36:5373-5379.
    PubMed     Text format     Abstract available


  119. HILAL Z, Schultheis B, Hartmann F, Dogan A, et al
    What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature.
    Anticancer Res. 2016;36:5365-5371.
    PubMed     Text format     Abstract available


  120. COBEC IM, Sas I, Pirtea L, Cimpean AM, et al
    Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer.
    Anticancer Res. 2016;36:5265-5272.
    PubMed     Text format     Abstract available


  121. GUI H, Guo XR, Fang J, Ma SN, et al
    The Tumor-promoting Effects of FAM92A1-289 in Cervical Carcinoma Cells.
    Anticancer Res. 2016;36:5197-5204.
    PubMed     Text format     Abstract available


  122. BOUSSIOS S, Zarkavelis G, Seraj E, Zerdes I, et al
    Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies.
    Anticancer Res. 2016;36:5031-5042.
    PubMed     Text format     Abstract available


  123. HAYASHI T, Kawano M, Ichimura T, Ida K, et al
    Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma.
    Anticancer Res. 2016;36:4997-5007.
    PubMed     Text format     Abstract available


  124. NAPOLETANO C, Bellati F, Ruscito I, Pernice M, et al
    Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells.
    Anticancer Res. 2016;36:5109-5116.
    PubMed     Text format     Abstract available


    September 2016
  125. BERTELLI G, Drews F, Lutchman-Singh K
    Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in 'Real-world' Patients.
    Anticancer Res. 2016;36:4947-50.
    PubMed     Text format     Abstract available


  126. NASSER S, Almuheimid J, Plett H, Sehouli J, et al
    Feasibility and Safety of Laparoscopic Total Mesometrial Resection in Early-stage Cervical Cancer.
    Anticancer Res. 2016;36:4903-7.
    PubMed     Text format     Abstract available


  127. PHILIP CA, Pelissier A, Bonneau C, Hequet D, et al
    Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2016;36:4865-71.
    PubMed     Text format     Abstract available


  128. KIM EY, Jun KH, Jung JH, Jo YS, et al
    Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report.
    Anticancer Res. 2016;36:4813-6.
    PubMed     Text format     Abstract available


  129. DZIGGEL L, Janssen S, Bajrovic A, Veninga T, et al
    Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers.
    Anticancer Res. 2016;36:4777-80.
    PubMed     Text format     Abstract available


  130. MUALLEM MZ, Almuheimid J, Richter R, Braicu EI, et al
    Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Anticancer Res. 2016;36:4707-13.
    PubMed     Text format     Abstract available


  131. BODNER-ADLER B, Kimberger O, Schneidinger C, Kolbl H, et al
    Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix.
    Anticancer Res. 2016;36:4691-6.
    PubMed     Text format     Abstract available


  132. CAPLAKOVA V, Babusikova E, Blahovcova E, Balharek T, et al
    DNA Methylation Machinery in the Endometrium and Endometrial Cancer.
    Anticancer Res. 2016;36:4407-20.
    PubMed     Text format     Abstract available


  133. HILAL Z, Hartmann F, Dogan A, Cetin C, et al
    Lymphoma of the Cervix: Case Report and Review of the Literature.
    Anticancer Res. 2016;36:4931-40.
    PubMed     Text format     Abstract available


    August 2016
  134. AUMIPHIN J, Crochet P, Knight S, Carcopino X, et al
    Outcome and Follow-up of Patients with Endometrial Carcinoma Diagnosed on Operative Hysteroscopic Resection Specimens.
    Anticancer Res. 2016;36:4341-5.
    PubMed     Text format     Abstract available


  135. MUALLEM MZ, Dimitrova D, Pietzner K, Richter R, et al
    Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology. A NOGGO-AGO* survey of 144 Gynecological Departments in Germany.
    Anticancer Res. 2016;36:4227-32.
    PubMed     Text format     Abstract available


  136. MUALLEM MZ, Sehouli J, Almuheimid J, Richter R, et al
    Risk Factors of Lymph Nodes Metastases by Endometrial Cancer: A Retrospective One-center Study.
    Anticancer Res. 2016;36:4219-25.
    PubMed     Text format     Abstract available


  137. PIMENTEL C, Becquet M, Lavoue V, Henno S, et al
    Ovarian Metastases from Breast Cancer: A Series of 28 Cases.
    Anticancer Res. 2016;36:4195-200.
    PubMed     Text format     Abstract available


  138. LOZNEANU L, Pinciroli P, Ciobanu DA, Carcangiu ML, et al
    Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
    Anticancer Res. 2016;36:4155-63.
    PubMed     Text format     Abstract available


  139. COIMBRA EC, DA Conceicao Gomes Leitao M, Junior MR, DE Oliveira TH, et al
    Expression Profile of MicroRNA-203 and its DeltaNp63 Target in Cervical Carcinogenesis: Prospects for Cervical Cancer Screening.
    Anticancer Res. 2016;36:3939-46.
    PubMed     Text format     Abstract available


    July 2016
  140. MIYAHARA D, Katsuta T, Maehara M, Takahashi Y, et al
    Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer.
    Anticancer Res. 2016;36:3725-9.
    PubMed     Text format     Abstract available


  141. HASHIMOTO K, Honda K, Matsui H, Nagashima Y, et al
    Flow Cytometric Analysis of Ovarian Cancer Ascites: Response of Mesothelial Cells and Macrophages to Cancer.
    Anticancer Res. 2016;36:3579-84.
    PubMed     Text format     Abstract available


  142. CHO O, Chun M, Chang SJ, Oh YT, et al
    Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Anticancer Res. 2016;36:3541-7.
    PubMed     Text format     Abstract available


  143. GADDUCCI A, Cosio S, Fanucchi A, Tana R, et al
    Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy.
    Anticancer Res. 2016;36:3477-82.
    PubMed     Text format     Abstract available


  144. OISHI S, Kudaka W, Toita T, Ariga T, et al
    Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.
    Anticancer Res. 2016;36:3471-5.
    PubMed     Text format     Abstract available


  145. SCHRODER L, Rudlowski C, Kutkuhn P, Abramian A, et al
    Impact of Open Laparoscopy in Patients Under Suspicion of Ovarian Cancer.
    Anticancer Res. 2016;36:3459-64.
    PubMed     Text format     Abstract available


  146. BOUNOUS VE, Ferrero A, Fuso L, Ravarino N, et al
    Endometriosis-associated Ovarian Cancer: A Distinct Clinical Entity?
    Anticancer Res. 2016;36:3445-9.
    PubMed     Text format     Abstract available


  147. PYLVAS-EEROLA M, Liakka A, Puistola U, Koivunen J, et al
    Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer.
    Anticancer Res. 2016;36:3425-31.
    PubMed     Text format     Abstract available


  148. STOPE MB, Hettenbach D, Kaul A, Paditz M, et al
    The Tumor Suppressor MicroRNA-1 Exhibits Restricted Inhibition of Proliferation of Ovarian Cancer Cells.
    Anticancer Res. 2016;36:3329-34.
    PubMed     Text format     Abstract available


  149. STOPE MB, Wiegank L, Weiss M, Diesing K, et al
    Drug-induced Modulation of Heat Shock Protein HSPB1 in an Ovarian Cancer Cell Model.
    Anticancer Res. 2016;36:3321-7.
    PubMed     Text format     Abstract available


    June 2016
  150. KOLBL AC, Wellens R, Koch J, Rack B, et al
    Endometrial Adenocarcinoma: Analysis of Circulating Tumour Cells by RT-qPCR.
    Anticancer Res. 2016;36:3205-9.
    PubMed     Text format     Abstract available


  151. STIASNY A, Kuhn C, Mayr D, Alexiou C, et al
    Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.
    Anticancer Res. 2016;36:3195-8.
    PubMed     Text format     Abstract available


  152. FREIER CP, Stiasny A, Kuhn C, Mayr D, et al
    Immunohistochemical Evaluation of the Role of p53 Mutation in Cervical Cancer: Ser-20 p53-Mutant Correlates with Better Prognosis.
    Anticancer Res. 2016;36:3131-7.
    PubMed     Text format     Abstract available


  153. BACALBASA N, Balescu I, Dima S, Popescu I, et al
    Hepatic Resection for Liver Metastases from Cervical Cancer Is Safe and May Have Survival Benefit.
    Anticancer Res. 2016;36:3023-7.
    PubMed     Text format     Abstract available


  154. NAKAMURA K, Nakayama K, Ishikawa M, Katagiri H, et al
    High Pre-treatment Plasma D-Dimer Level as a Potential Prognostic Biomarker for Cervical Carcinoma.
    Anticancer Res. 2016;36:2933-8.
    PubMed     Text format     Abstract available


  155. PILKA R, Marek R, Adam T, Kudela M, et al
    Systemic Inflammatory Response After Open, Laparoscopic and Robotic Surgery in Endometrial Cancer Patients.
    Anticancer Res. 2016;36:2909-22.
    PubMed     Text format     Abstract available


  156. CACAN E
    Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells.
    Anticancer Res. 2016;36:2819-26.
    PubMed     Text format     Abstract available


  157. ARZUMAN L, Beale P, Yu JQ, Huq F, et al
    Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines.
    Anticancer Res. 2016;36:2809-18.
    PubMed     Text format     Abstract available


    April 2016
  158. TANAKAYA K, Yamaguchi T, Ishikawa H, Hinoi T, et al
    Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.
    Anticancer Res. 2016;36:1985-9.
    PubMed     Text format     Abstract available


  159. LALISCIA C, Fabrini MG, Delishaj D, Coraggio G, et al
    Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study.
    Anticancer Res. 2016;36:1885-9.
    PubMed     Text format     Abstract available


    March 2016
  160. KACPERCZYK J, Bartnik P, Romejko-Wolniewicz E, Jalinik K, et al
    Results of Further Diagnostic Procedures Among Patients with Cytological Characteristics of Minor Changes on Pap Smears.
    Anticancer Res. 2016;36:1023-6.
    PubMed     Text format     Abstract available


    January 2016
  161. LALISCIA C, Gadducci A, Montrone S, Tana R, et al
    Radiotherapy as Definitive Treatment of Patients with Primary Vulvar Carcinoma Unfit for Surgery and with Recurrent Vulvar Carcinoma After Primary Radical Surgery: Results of a Retrospective Single-center Study.
    Anticancer Res. 2016;36:387-91.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: